The Roles of Exosomal Circ-LRBA and 451/CRTC2 Signaling Axis in Colorectal Cancer

Sponsor

Jingbo Chen (Other)

Overall Status

Recruiting

CT.gov ID

NCT05579353

Collaborator

(none)

200

Enrollment

Location

Anticipated Duration (Months)

4.2

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Colorectal cancer (CRC) is one of the most common malignant tumors in the world. Most of the patients with colorectal cancer were diagnosed in poor stage. Although 40% to 50% patients of colorectal cancer can be cured by surgery, but most patients have undergent metastasis or recurrence, and eventually death. In recent years, molecular targeted therapy has shown significant efficacy in specific patients. It was necessary to detect the corresponding molecular targets of tumors before selecting appropriate targeted drugs in clinic. The changing state of related gene molecules in colorectal cancer played a key role in drug selection, there were few effective targets so far. At present, metastasis and recurrence still be the most difficult problems in treatment. Therefore, investigators should deeply study the occurrence and development of colorectal cancer at the gene level and look for new biomarkers to predict the prognosis. Furthermore, the study can clarify the exact molecular mechanism of colorectal cancer. These will be important clinical significance for targeted therapy of colorectal cancer.

Condition or Disease	Intervention/Treatment	Phase
Colorectal Cancer	Other: nothing

Study Design

Study Type:

Observational

Anticipated Enrollment :

200 participants

Observational Model:

Cohort

Time Perspective:

Retrospective

Official Title:

The Roles and Molecular Mechanism of Exosomal Circ-LRBA That Regulates miR-451/CRTC2 Signaling Axis in Colorectal Cancer Progression

Anticipated Study Start Date :

Jan 1, 2023

Anticipated Primary Completion Date :

Jun 30, 2025

Anticipated Study Completion Date :

Dec 31, 2026

Arms and Interventions

Arm	Intervention/Treatment
cancer group	Other: nothing nothing
control group	Other: nothing nothing

Arm

Intervention/Treatment

cancer group

Other: nothing

nothing

control group

Other: nothing

nothing

Outcome Measures

Primary Outcome Measures

expressional quantity [Through study completion, an average of 2 year]
Expression of CRTC2 in patient samples

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years to 80 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Yes

Inclusion Criteria:

1.18-80 years old.

2.18.5 < BMI < 27.9.

The surgical methods are radical resection of rectal cancer, resection of right colon cancer, resection of left colon cancer and radical resection of sigmoid colon cancer.

Exclusion Criteria:

Those who refuse to collect samples.
Patients with severe dysfunction of coagulation, hepatorenal dysfunction or severe cardiopulmonary diseases.
Patients who has a history of neoadjuvant radiotherapy or chemotherapy.
Combining with distant multiple metastases of tumor

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	The First Affiliated Hospital of Shandong First Medical University	Jinan	Lixia	China	250014

Sponsors and Collaborators

Jingbo Chen

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

Responsible Party:

Jingbo Chen, Professor, Qianfoshan Hospital

ClinicalTrials.gov Identifier:

NCT05579353

Other Study ID Numbers:

YXLL-KY-2022

First Posted:

Oct 13, 2022

Last Update Posted:

Oct 13, 2022

Last Verified:

Oct 1, 2022

Individual Participant Data (IPD) Sharing Statement:

Yes

Plan to Share IPD:

Yes

Studies a U.S. FDA-regulated Drug Product:

Studies a U.S. FDA-regulated Device Product:

Additional relevant MeSH terms:

Colorectal Neoplasms

Study Results

No Results Posted as of Oct 13, 2022